GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (NAS:RARE) » Definitions » Equity-to-Asset

Ultragenyx Pharmaceutical (Ultragenyx Pharmaceutical) Equity-to-Asset

: 0.19 (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Ultragenyx Pharmaceutical's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $275.4 Mil. Ultragenyx Pharmaceutical's Total Assets for the quarter that ended in Dec. 2023 was $1,491.0 Mil. Therefore, Ultragenyx Pharmaceutical's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.19.

The historical rank and industry rank for Ultragenyx Pharmaceutical's Equity-to-Asset or its related term are showing as below:

RARE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.19   Med: 0.72   Max: 0.95
Current: 0.19

During the past 13 years, the highest Equity to Asset Ratio of Ultragenyx Pharmaceutical was 0.95. The lowest was 0.19. And the median was 0.72.

RARE's Equity-to-Asset is ranked worse than
80.08% of 1566 companies
in the Biotechnology industry
Industry Median: 0.66 vs RARE: 0.19

Ultragenyx Pharmaceutical Equity-to-Asset Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.66 0.61 0.23 0.19

Ultragenyx Pharmaceutical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.16 0.10 0.03 0.19

Competitive Comparison

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Equity-to-Asset falls into.



Ultragenyx Pharmaceutical Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Ultragenyx Pharmaceutical's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=275.414/1491.013
=0.18

Ultragenyx Pharmaceutical's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=275.414/1491.013
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ultragenyx Pharmaceutical  (NAS:RARE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Ultragenyx Pharmaceutical Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultragenyx Pharmaceutical (Ultragenyx Pharmaceutical) Business Description

Traded in Other Exchanges
Address
60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Executives
Emil D Kakkis director, 10 percent owner, officer: President & CEO C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Thomas Richard Kassberg officer: CBO & Senior Vice President C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Howard Horn officer: Chief Financial Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Theodore Alan Huizenga officer: Controller and PAO C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Erik Harris officer: EVP & Chief Commercial Officer 60 LEVERONI COURT, NOVATO CA 94949
Sanders Corazon (corsee) D. director C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
John Richard Pinion officer: See Remarks C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Karah Herdman Parschauer officer: EVP and General Counsel 60 LEVERONI COURT, NOVATO CA 94949
Eric Crombez officer: EVP and Chief Medical Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Dennis Karl Huang officer: SVP and Chief Tech Ops Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Camille L Bedrosian officer: EVP and Chief Medical Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Mardi Dier officer: CFO & Executive Vice President C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Amrit Ray director 60 LEVERONI COURT, NOVATO CA 94949
William Aliski director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Shalini Sharp officer: CFO & Senior Vice President C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949